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Abstract
A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD
1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6,
revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine
ring with 4-quinoline. The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-
a]pyrimidine ring were also examined by preparing and evaluating pyrrolo[1,2-a]pyrimidine and
pyrazolo[1,5-a]pyridine derivatives. In addition, increased mouse liver microsome stability was
achieved by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an
optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic
characteristics (e.g. plasma t1/2 = 1.6 h) following intraperitoneal administration in mice. These
studies provide useful molecular probes for examining the in vivo pharmacology of BMP signaling
inhibition.
Bone morphogenetic proteins (BMPs) are a group of > 25 protein ligands that comprise a subset
of the transforming growth factor β (TGF-β) family. BMPs modulate a multitude of biological
processes, including bone and cartilage formation during embryogenesis.1a However, they are
also intimately involved with numerous nonosteogenic developmental and physiological
processes throughout adulthood as well as several pathological conditions.
BMPs bind to two classes of cell surface bone morphogenetic protein receptors (BMPR-I and
BMPRII).1a The BMPR-I receptor class consists of three receptor types, activin receptor-like
kinase-2 (ALK-2 or ActR-IA), ALK-3 (BMPR-IA) and ALK-6 (BMPR-IB). The BMPR-II
receptor class is comprised of three receptor types, BMPR-II, ActR-IIA and ActR-IIB. Binding
of BMPs results in the formation of heterotetrameric complexes containing two type I and two
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type II receptors. In addition to an extracellular binding domain, each BMP receptor contains
an intracellular serine/threonine kinase domain. Following binding of BMPs, constitutively
active type II receptor kinases phosphorylate type I receptor kinase domains that in turn
phosphorylate BMP-responsive SMADs 1, 5, and 8, which can enter the cell nucleus and
function as transcription factors.1b Phosphorylation of these specific SMADs results in various
cellular effects, including growth regulation and differentiation. Signaling via BMP receptors
may also activate other pathways, including mitogen activated protein kinase (MAPK).1c
Several diseases are known to arise from inborn defects in the BMP signaling pathway,
including idiopathic pulmonary arterial hypertension,2 hereditary hemorrhagic telangiectasia
syndrome and juvenile familial polyposis syndrome,3 all of which involve loss-of-function
mutations in BMP receptors or co-receptors. Acquired defects in the BMP signaling pathway
are thought to contribute to metastasis of prostate carcinoma4 and renal cell carcinoma.5 Other
disorders, such as fibrodysplasia ossificans progressiva (FOP)6 and anemia of chronic
disease7 may result from increased BMP signaling. For conditions where increased BMP
signaling contributes to disease pathogenesis, inhibitors may offer therapeutic benefit.
Inhibition of BMP signal transduction could be envisioned to occur through various
mechanisms, including antagonizing BMP binding to BMPRs or inhibition of the intracellular
BMP receptor kinase activity.8 Numerous endogenous protein antagonists that sequester BMP
ligands preventing engagement with BMP receptors are known, including noggin, follistatin,
chordin and gremlin. Small molecule antagonists of the BMP ligand-receptor interaction have
not been identified, possibly due to difficulties antagonizing this protein-protein interaction.
9 In addition, the structural diversity of BMP receptors and ligands, and functional redundancy
of both systems might pose a challenge for effective blockade of extracellular domains.
However, inhibition of SMAD phosphorylation by BMPR-I intracellular kinase domains with
small molecules may provide more efficient signal transduction pathway inhibition. This latter
approach has been used to identify inhibitors (i.e. SB-431542) of the TGF-β1 receptor kinase
ALK5.10
Recently, dorsomorphin, 1,7a, 11, 12 was discovered as an inhibitor of SMAD 1/5/8
phosphorylation by BMP type 1 receptors (ALK2, 3, and 6) utilizing a phenotypic screen to
identify compounds that perturb embryonic dorsoventral axis formation. Furthermore, this
inhibition was shown to decrease BMP-regulated hepatic hepcidin gene transcription, leading
to increased iron levels in vivo.7a However, 1 only demonstrated moderate inhibition of SMAD
1/5/8 phosphorylation by BMPR-I with an IC50 ~ 0.5 µM and lacks metabolic stability. Herein,
we describe the results of a structure-activity relationship (SAR) study to optimize BMP
signaling inhibition of SMAD 1/5/8 phosphorylation. In addition, we addressed the metabolic
stability of this compound series and report a pharmacokinetic study for an optimized
derivative.
The synthesis of substituted pyrazolo[1,5-a]pyrimidine derivatives was initially accomplished
according to Scheme 1 (Method A). Arylacetonitriles, 2, were allowed to react with
dimethyformamide dimethylacetal (DMFDMA) to give 3. In the case of pyridine or quinoline
acetonitrile salts, an equivalent of triethylamine was also added. Cyclization of 3 in the presence
of hydrazine hydrobromide gave 2-amino-1H-pyrazoles 4a. Condensation of 4a – c with
various malondialdehydes in acetic acid and ethanol either under conventional or microwave
(MW)13 heating yielded pyrazolo[1,5-a]pyrimidine derivatives 5a – c. In the case of 5c,
palladium-mediated cross-coupling with arylboronic acids also gave 5a. This reaction was
useful for preparing derivatives where the corresponding arylacetonitriles were not readily
available. Dealkylation of the 3- or 4-methoxy ethers on the pendent phenyl rings was
accomplished with hydrobromic acid in acetic acid with microwave heating to give 6. Finally,
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alkylation in one step with R2N(CH2)nCl or in two steps with Cl(CH2)nCl followed by amine
addition gave 7.
Two other routes were subsequently developed for the synthesis of pyrazolo[1,5-a]pyrimidine
derivative 1314 and other analogs that contained an amine on the 3- or 4- position of the pendent
phenyl ring. The first alternate route, depicted in Scheme 2 (Method B), began in a similar
manner as previously described starting with 815, except that 2-(4-bromophenyl)
malondialdehyde was used to generate 11. Next, a palladium-mediated cross coupling with N-
Cbz-piperazine yielded 12. Removal of the benzyl carbamate by hydrogenation (1 atm) in the
presence of 5% Pd/C gave 13.
The second alternate route to 13, depicted in Scheme 3 (Method C), began with 2-amino-1H-
pyrazole, 4b, which was allowed to react with 2-bromomalondialdehyde to give 6-
bromopyrazolo[1,5-a]pyrimidine, 15a. A palladium-mediated cross-coupling with 4-4-(tert-
butoxycarbonyl)-piperazin-1-ylphenylboronic acid pinacol ester yielded 16. Next, a
regioselective bromination of the C-3 carbon with N-bromosuccinimide (NBS) in
dichloromethane at room temperature gave 17a in 79% yield. Palladium-mediated cross-
coupling of this aryl bromide with quinoline-4-boronic acid produced 18a in a moderate 46%
yield. Finally, deprotection of the tert-butyl carbamate with 4N HCl in a mixture of 1,4-dioxane
and methanol gave 13 as the hydrochloride salt. This method was also used to prepare several
other derivatives, including 18c that contains a C-2 substituent.
The synthesis of pyrrolo[1,2-a]pyrimidine derivatives is illustrated in Scheme 4 (Method D).
2-Trichloromethylketopyrrole, 19, was regioselectively brominated affording 20.16 Next,
regioselective nitration with concentrated nitric acid gave 21.17 This compound was allowed
to react with sodium methoxide in methanol producing the methyl ester 22. Palladium-
mediated cross-coupling of this pyrrole bromide with quinoline-4-boronic acid generated 23
in 60% yield.12a Reduction of the nitro group with hydrogen (1 atm) in the presence of 10%
Pd/C gave 24, which was used immediately without purification. Condensation with 2-(4-
methoxyphenyl)malondialdehyde in acetic acid and ethanol yielded pyrrolo[1,2-a]pyrimidine
derivative 25. Heating this material at 110 °C in aqueous sulfuric acid for 2 h gave 26 via ester
hydrolysis and subsequent decarboxylation.18 Prolonged heating of 25 for 2 days resulted in
ether hydrolysis producing 27. Finally, alkylation of the phenol afforded 28.
The synthesis of pyrazolo[1,5-a]pyridine derivatives is outlined in Scheme 5 (Method E). A
palladium-mediated cross-coupling of 3-bromopyridine, 29, with 4-methoxyphenylboronic
acid produced 30 in 58% yield.19 This pyridine derivative was converted to the 1-
aminopyridinium salt 31a utilizing O-(2,4-dinitrophenyl)hydroxylamine.20 Cyclization of
31a upon treatment with methyl propiolate gave regioisomers 32a and 32b in a 1:2 ratio and
a combined yield of 33% over two steps.21 In a similar manner, 29 was converted to 33a and
33b (1:2 ratio) in 37% yield, via intermediate 31b. Compound 33a was further converted to
34 via a palladium-mediated coupling. Then, 32a and 34 were hydrolyzed with aqueous sodium
hydroxide and the resulting carboxylic acids were subjected to metal-mediated decarboxylative
coupling22 with 4-bromoquinoline in the presence of Pd(acac)2 and CuI producing 35 and
36, respectively, albeit in low yields (10 – 22%). Finally, exposure of 36 to 4N HCl in 1,4-
dioxane resulted in removal of the tert-butyl carbamate yielding 37 as the hydrochloride salt.
Evaluation of BMP4-induced phosphorylation of SMAD1/5/8 was performed using a sensitive
cytoblot cellular ELISA assay in the presence of varying concentrations of test compounds.
23a,b Functional IC50 values were calculated for the inhibitory effects of test compounds on
phosphorylation of SMAD1/5/8 and are shown in Table 1 - Table 3.23c
Introduction of an aminoether at the 4-position of the pendent phenyl ring on the pyridine
derivatives (e.g. 1 and 39 – 41 vs. 38) increased activity three to fifteen fold in addition to
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improving aqueous solubility (Table 1). Introduction of a substituent on the 2-position of the
pyrazolo[1,5-a]pyrimidine ring (43) abolished activity. In addition, activity was dramatically
affected by the nature of the substituent on the 3-position of the pyrazolo[1,5-a]pyrimidine
ring. Removal (44) or replacement of the 4-pyridyl in 1 with 3-pyridyl (45) or phenyl (46)
resulted in complete loss of activity. Replacement of the pyridine ring with 3-fluoro-4-pyridyl
(47) likewise resulted in reduced activity.
Due to these significant substituent effects on the 3-position of the pyrazolo[1,5-a]pyrimidine
ring and the demonstrated influence of heterocyclic substituents on other TGF-β receptor type
inhibitors,24 quinolines attached through various positions were examined (Table 2). In
compound 52, where the pyrazolo[1,5-a]pyrimidine ring is connected to the 4-position of the
quinoline, a significant increase in activity was observed. Introduction of an aminoether to the
4-position of the pendent phenyl ring (53) increased potency as was previously observed for
the pyridine derivatives (vida supra). Replacing the aminoether with piperazine (13) was also
well tolerated. However, transposing this substituent to the 3-position of the pendent phenyl
(58) resulted in significant loss of activity. Likewise, introduction of a chloride to the 7-position
of the quinoline ring (59 vs. 52 and 60 vs. 13) resulted in decreased activity.
Next, the contributions of the nitrogen atoms in the 1- and 4-positions of the pyrazolo[1,5-a]
pyrimidine ring were examined (Table 3). The importance of the N-1, but not the N-4, nitrogen
atoms was previously demonstrated for KDR kinase inhibition by pyrazolo[1,5-a]pyrimidine
derivatives.25 Similarly, in the present series of compounds the N-1 (28 vs. 54) appears
necessary for potent inhibition of BMP4-induced phosphorylation of SMAD1/5/8, whereas the
N-4 was not essential (37 vs. 13).
Both the original lead compound 1 and a more potent derivative 53 demonstrated poor
metabolic stability in mouse liver microsomes (1: half-life (t1/2) of 10.4 min and intrinsic
clearance (CLint) of 133 ± 6.6 µL/min/mg protein; 53: t1/2 of 13.3 min and CLint of 104 ± 3.4
µL/min/mg protein).23b, 26 However, replacement of the ether on the pendent phenyl ring
with piperazine resulted in a significant increase in mouse liver microsome stability. For
example, 13 demonstrated a t1/2 of 82 min and CLint of 16.9 ± 5.6 µL/min/mg protein. Based
on the potency and metabolic stability of 13, it was selected for in vivo pharmacokinetic analysis
following a single bolus intraperitoneal (ip) administration of 3 mg/kg in male and female
C57B16 mice.23b The results of this study are shown in Table 4. The pharmacokinetics of
13 was similar in both male and female mice. The average maximal plasma concentrations
were slightly higher in males (1.54 µM) than in females (1.29 µM) and were reached quickly
(> 5 min) following administration. The plasma half-life (1.6 h) and the average AUC∞ values
(994 and 1030 ng·h/mL) were similar in male and female mice.
In conclusion, a structure-activity relationship study of dorsomorphin, 1, a previously identified
inhibitor of SMAD 1/5/8 phosphorylation by BMP type 1 receptors ALK2, 3, and 6, revealed
that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine
ring with 4-quinoline. The nitrogen atom in the 1-position of the pyrazolo[1,5-a]pyrimidine
ring was determined to be necessary for inhibitory activity. However, the nitrogen atom in the
4-position was not vital. In addition, increased mouse liver microsome stability was achieved
by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an
optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic
characteristics (e.g. plasma t1/2 = 1.6 h) following intraperitoneal administration in mice.
Evaluation of this inhibitor in various animal disease models in which BMP signaling has been
hypothesized to play a role, such as FOP and anemia of chronic disease, are currently on-going.
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Figure 1.
BMP signaling inhibitor of SMAD 1/5/8 phosphorylation.
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Scheme 1.
(Method A). Reagents and conditions: (a) (MeO)2CHNMe2, Et3N (for pyridine and quinoline
salts), DMF, 110 °C, 4 – 6 h, 100%; (b) NH2NH2·HBr, EtOH/H2O, 110 °C, 6 h, 45 – 80%; (c)
ArCH(CHO)2, AcOH, EtOH, 110 °C, 6 h (or MW, 170 °C, 5 min); (d) ArB(OH)2,
Pd2(dba)3, 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, K3PO4, n-BuOH, MW, 150
°C, 8 min, 84 – 90%; (e) HBr/HOAc, MW, 130 °C, 8 min, 65 – 86%; (f) R2N(CH2)nCl·HCl,
Cs2CO3, NaI (cat), DMF, 60 °C, 3 h, (or MW, 140 °C, 6 min), 30 – 75% or Cl(CH2)nCl,
K2CO3, DMF, MW, 140 °C, 6 min, then R2NH, NaI (cat), DMF, MW, 150 °C, 10 min, 30 –
60%.
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Scheme 2.
(Method B). (a) (MeO)2CHNMe2, 110 °C, 16 h, 100%; (b) NH2NH2·HBr, EtOH/H2O, 110 °
C, 4 h, 80%; (c) 4-BrPhCH(CHO)2, AcOH, EtOH, MW, 170 °C, 5 min, 54%; (d) N-Cbz-
piperazine, Pd2(dba)3, (2-biphenylyl)di-tert-butylphosphine, KOBu-t, DME, 100 °C, 20 h, 20
– 30%; (e) H2 (1 atm), 5% Pd/C (57% H2O), MeOH/CH2Cl2, rt, 4h, 86%.
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Scheme 3.
(Method C). (a) BrCH(CHO)2 (or 4-OMePhCH(CHO)2 for 15b) AcOH, EtOH, 80 °C, 7 h,
49%; (b) B(O[C(CH3)2]2O)-4-Ph-N-Boc-piperazine, Pd(PPh3)4, K2CO3, dioxane/H2O, MW,
150 °C, 8 min, 90% (or 110 °C, 3 h, 86%); (c) NBS, CH2Cl2, rt, 5 h, 79%; (d) quinoline-4-
boronic acid, Pd2(dba)3, 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, K3PO4, n-
BuOH, MW, 150 °C, 15 min, 46%; (e) 4 N HCl in 1,4-dioxane, MeOH, rt, 24 h, 95%; (f) HBr/
HOAc, MW, 130 °C, 8 min, 81%; (g) Cl(CH2)2Cl, K2CO3, DMF, MW, 140 °C, 6 min, then
N-Me-piperizine, NaI (cat), DMF, MW 150 °C, 10 min, 57%.
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Scheme 4.
(Method D). (a) Br2, CHCl3, 0 °C, 57%; (b) HNO3 (70%), Ac2O, −40 °C to rt, 40 %; (c)
NaOMe, MeOH, rt, 99%; (d) quinoline-4-boronic acid, Pd(PPh3)4, Na2CO3, 1,4-dioxane,
reflux, 16 h, 60 %; (e) H2 (1 atm), 10% Pd/C, MeOH, rt, 0.5 h; (f) 4-MeOPhCH(CHO)2, AcOH,
EtOH, reflux, 16 h, 73 %; (g) 40% aqueous H2SO4, 110 °C, 2 h, 91 %; (h) 40% aqueous
H2SO4, 110 °C, 2 days, 71 %; (i) piperidyl-NCH2CH2Cl·HCl, 60 % NaH, DMF, rt, 24 h, 80
%.
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Scheme 5.
(Method E). (a) 4-MeOPhB(OH)2, Pd(PPh3)4, K3PO4, 1,4-dioxane, 100 °C, 18 h, 58%; (b)
2,4-di-NO2PhONH2, CH3CN, 40 °C, 20 h; (c) HC≡CCO2Me, K2CO3, DMF, rt, 33 – 37% over
two steps (32a:32b and 33a:33b ~ 1:2); (d) B(O[C(CH3)2]2O)-4-Ph-N-Boc-piperazine, Pd
(PPh3)4, K2CO3, 1,4-dioxane/H2O, 110 °C, 5 h, 73%; (e) NaOH, EtOH/H2O (6:1), Δ, 3 h; (f)
4-bromoquinoline, Pd(acac)2, CuI, K2CO3, 1,10-phenanthroline, 4Å MS, NMP, 165 °C, 24 h,
10 – 22% (over two steps); (g) 4N HCl in 1,4-dioxane, MeOH, rt, 24 h.
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